Adare Pharmaceuticals

Oral Drug Delivery Technologies and Drug Development

Princeton Pike Corporate Center , 1200 Lenox Drive, Suite 100, Lawrenceville, 08648,New Jersey, United States of America

Princeton Pike Corporate Center , 1200 Lenox Drive, Suite 100, Lawrenceville, 08648,New Jersey, United States of America



Taste masking and customised drug development

Adare Pharmaceuticals transforms medicines, creating new possibilities for improved patient health.

For decades, the company has successfully overcome complex formulation challenges in specialized and diverse therapeutic categories such as cardiovascular, pain management, gastrointestinal (GI) and central nervous system (CNS), delivering medicines that benefit patients.

Using proprietary technologies, including taste masking and orally disintegrating tablets (ODT), customized drug release, and bioavailability enhancement, Adare has demonstrated the unique ability to transform drug formulations and create novel Rx and over-the-counter (OTC) products.

In addition, Adare can add valuable IP to commercialized products and products in development for business partners worldwide. With global research and development (R&D) and manufacturing facilities, Adare brings complex products from development to commercialization.

Since 2009, Adare’s partnerships have resulted in more than 60 product launches in 44 countries.

Taste masking technology platform

Adare offers proprietary technologies that provide taste masked products with a pleasant taste and excellent mouth-feel for patient appeal. These technologies include AdvaTab®, Liquitard®, and Microcaps®.

Customized drug release technology platform

The customized drug release technology platform consists of various technologies that provide a range of customized release profiles. These drug release profiles can be tailored to optimize a drug’s therapeutic performance by improving efficacy and enhancing safety.

Patient acceptability and compliance can be increased through less frequent dosing. Adare’s proprietary customized drug release technologies include Diffucaps®, Eurand Minitabs®, and Diffutab®.

Bioavailability enhancement technology platform

Adare provides technologies to enable and improve the bioavailability of drugs with low solubility or an extreme pH-dependent solubility profile.

The resulting formulations can offer effective oral dosing of poorly soluble drug candidates, equivalent therapy at lower doses, faster onset of action, and minimization of food effect. The bioavailability enhancement technologies provided by Adare include Biorise™ and Diffucaps® (solid solution or solid dispersion).

Collaborations and clients

The company meets its partners’ business needs by offering technologies and resources for the development of new product formulations or licensing availability of existing product formulations (both Rx and OTC.)

Adare’s partnership process provides its clients with an experienced management team across all functions and stages of the product development cycle.

Adare has a multinational infrastructure and integrated R&D and manufacturing facilities in the US and Europe, thereby delivering global solutions to companies in various regions worldwide.

The company’s global business development and licensing teams aim to provide flexible deal structures to help maximize its partners’ interests.

Forest Laboratories to Acquire Aptalis

Aptalis has signed a definitive agreement to be acquired by Forest Laboratories, a leading, fully integrated, specialty pharmaceutical company, for $2.9bn in cash pending required reviews.

Aptalis Pharmaceutical Technologies Expands Licensing Team

Aptalis Pharmaceutical Technologies, a business unit of Aptalis Pharma that develops differentiated products utilizing its oral delivery technologies, today announces that Nigel Ray has been named as the company's Vice President of Global Licensing.

Aptalis Announces European Commission Approval for New Formulation of Viread®

Aptalis Pharmaceutical Technologies, formerly Eurand Pharmaceutical Technologies, focused on developing differentiated oral products utilising its pharmaceutical technologies, today announced that the European Commission has granted marketing authorisation for a new pediatric indication of a new oral granule formulation of Gilead Sciences's Viread® (tenofovir disoproxil fumarate) for HIV-1 infected children aged two to six years of age, and for HIV-1 infected children above six years of age for whom a solid dosage form is not appropriate.

PharmaTelevision Interview to Spotlight Aptalis Pharma’s Year in Review

FDA approvals, revenue gain and organic business growth are just a few of the topics that Aptalis Pharma president John Fraher addresses during an on-air interview with PharmaVentures and PharmaTelevision CEO Fintan Walton. The interview, conducted during BIO 2012 in Boston, reflects Fraher's commentary regarding the integration of companies post Axcan Intermediate Holdings' acquisition of Eurand NV in 2011.

Aptalis Wins Appeal Against Generic Version of AMRIX

Aptalis (previously known as Eurand, Inc.), Cephalon, a wholly-owned subsidiary of Teva Pharmaceuticals Industries Ltd, and Anesta AG prevailed in their appeal to the U.S. Court of Appeals for the Federal Circuit, which reversed a lower court's determination and held that two patents covering the AMRIX muscle relaxant (Cyclobenzaprine Hydrochloride Extended-Release Capsules) are valid.

PharmaTelevision Interview to Spotlight Aptalis Pharma President John Fraher

Company strategy, portfolio development and emerging markets are just a few of the topics that John Fraher, president of Aptalis Pharma, is scheduled to address during an on-air interview with Fintan Walton, CEO, PharmaVentures and PharmaTelevision. The interview is available via on-demand at Pha

Eurand to Discuss Strategic Decision-Making at BioEurope Spring

Steve Ellul, Eurand's director of licensing, will discuss aspects of the company's growth strategy during the session 'Understanding the Drivers for Strategic Decision-Making' at BioEurope Spring in Milan, Italy, on Monday 14 March from 9am to 10.30am local time. The panel of industry

Eurand Enters Agreement With Nycomed for ZENPEP in Russia-CIS

Eurand, a global specialty pharmaceutical company, and Nycomed, a privately owned global pharmaceutical company, have announced an exclusive commercialization, license and supply agreement for Russia and the Commonwealth of Independent States (CIS), as well as Georgia and Mongolia. Financial term

Eurand Presents Taste-Masking Technology Webinar

Eurand, a global specialty pharmaceutical company, has conducted a webinar titled 'The $10 Billion Gap: Leveraging Taste-Masking Technologies to Meet Global Patient Needs', presented by Troy Harmon, vice president of business development, and Andrew Thompson, vice president of commercial operatio

Eurand Reports Recent Highlights and Second Quarter 2010 Financial Results

Eurand, a global specialty pharmaceutical company, today reported revenues for the second quarter of 2010 of €32.9m ($40.5m), an increase of 8%, or 3% in constant currency, from the second quarter of 2009. For the six months ended 30 June 2010, revenues totaled €64m ($78.7m), up

Eurand Issued US Patent for ZENPEP (pancrelipase) Delayed-Release Capsules

Eurand, a global specialty pharmaceutical company, announced today the grant of US Patent No. 7,658,918, titled 'Stable digestive enzyme compositions', by the United States Patent and Trademark Office (USPTO). The patent will provide Eurand with coverage until at least 20 February 2028 on ZENPEP&

Adare Pharmaceuticals

Princeton Pike Corporate Center

1200 Lenox Drive, Suite 100

Lawrenceville

08648

New Jersey

United States of America

+1 609 450 1312 www.adarepharma.com
Adare Pharmaceuticals

Via Martin Luther King, 13

20060, Pessano con Bornago

Milan

Bologna

Italy

Adare Pharmaceuticals

845 Center Drive

Vandalia

45377

Ohio

United States of America